结合
胰岛素
右旋糖酐
琥珀酸酐
化学
共轭体系
生物利用度
纳米颗粒
生物化学
药理学
有机化学
聚合物
内科学
材料科学
纳米技术
生物
医学
数学分析
数学
作者
Kishore B. Chalasani,Gregory Russell‐Jones,Akhlesh Kumar Jain,Prakash V. Diwan,Sanjay Jain
标识
DOI:10.1016/j.jconrel.2007.05.019
摘要
The potential utility of vitamin B12 carrier system for the oral delivery of conjugated peptides/proteins and enhancement of nanoparticles (NPs) transport has been demonstrated. The present study aims to optimize the effectiveness of VB12–NPs conjugates using different levels of cross-linking, linked with different VB12-coatings and evaluates in animal models to investigate an efficient insulin carrier. Amino alkyl VB12 derivatives suitable for oral delivery were synthesized at 5′hydoxy ribose and e-propionamide sites via carbamate and ester/amide linkages, and were coupled to succinic acid modified dextran NPs of varied cross-linking. VB12 binding was confirmed by XPS analysis, and was quantified by HPLC (4.0 to 5.7% w/w of NPs). These polydisperse NPs conjugates showed higher size, high insulin entrapment and faster insulin release with low levels of cross-linking. These VB12–NPs conjugates (150–300 nm) showed profound (70–75% blood glucose reductions) and prolonged (54 h) anti-diabetic effects with biphasic behaviour in STZ diabetic rats. NPs with the low levels of cross-linking were found to be superior carriers, and were more effective with VB12 derivatives of carbamate linkage. The pharmacological availability relative to SC insulin was found to be 29.4%, which was superior compared to NPs conjugate of ester linked VB12 (1.5 fold) and relatively higher cross-linked particles (1.1 fold). Further, the NPs carrier demonstrated a similar oral insulin efficacy in congenital diabetic mice (60% reduction at 20 h). Significant quantities of plasma insulin were found in both animal models (231 and 197 μIU/ml). At two investigated doses, the carrier system shows dose response. Pre-dosing with a large excess of free VB12 minimized the observed activity, indicating predominance of VB12 mediated uptake. It is concluded that VB12–dextran NPs conjugate is a viable carrier for peroral insulin delivery to treat diabetics.
科研通智能强力驱动
Strongly Powered by AbleSci AI